Veterinary Medicines

Febrivac 3-Plus injektioneste, suspensio

Authorised
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
  • Clostridium botulinum, type C, toxoid
  • Mink enteritis virus, type 1, strain United, Inactivated
Download as PDF

Product identification

Medicine name:
Febrivac 3-Plus injektioneste, suspensio
Active substance:
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
  • Clostridium botulinum, type C, toxoid
  • Mink enteritis virus, type 1, strain United, Inactivated
Target species:
  • Mink
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
    8.00
    log10 cell count
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
    8.00
    log10 cell count
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
    8.00
    log10 cell count
    /
    1.00
    millilitre(s)
  • Clostridium botulinum, type C, toxoid
    0.50
    unit(s)
    /
    1.00
    millilitre(s)
  • Mink enteritis virus, type 1, strain United, Inactivated
    4.00
    log10 tissue culture infective dose 50
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Mink
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI20CL01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Finland
Package description:
  • 500 ml vial
  • 250 ml vial
  • 50 ml vial

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • IDT Biologika GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • IDT Biologika GmbH
Responsible authority:
  • Finnish Medicines Agency
Authorisation number:
  • 13860
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 30/08/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 30/08/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."